SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 8,618.69 |
| Enterprise Value ($M) | 9,346.69 |
| Book Value ($M) | 3,567.34 |
| Book Value / Share | 16.51 |
| Price / Book | 2.42 |
| NCAV ($M) | -162.43 |
| NCAV / Share | -0.75 |
| Price / NCAV | -53.06 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.02 |
| Return on Assets (ROA) | 0.01 |
| Return on Equity (ROE) | 0.02 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.09 |
| Current Ratio | 3.61 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 1,959.85 |
| Assets | 5,689.62 |
| Liabilities | 2,122.28 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 1,978.21 |
| Operating Income | 498.80 |
| Net Income | 83.59 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 673.55 |
| Cash from Investing | -249.23 |
| Cash from Financing | -422.90 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Wellington Management Group Llp | 10.70 | 9.60 | |
| 13G | BlackRock, Inc. | 10.20 | 2.53 | |
| 13G/A | Massachusetts Financial Services Co /ma/ | 10.50 | -0.26 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 169,202 | 810,240 | 20.88 | |
| 285,984 | 1,791,035 | 15.97 | |
| 94,419 | 722,001 | 13.08 | |
| 105,058 | 649,111 | 16.18 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| PBH – Prestige Consumer Healthcare Inc. | PFE – Pfizer Inc. |
| PRGO – Perrigo Company plc | RCUS – Arcus Biosciences, Inc. |
| RFL – Rafael Holdings, Inc. |
Financial data and stock pages provided by
Fintel.io